Letters
Cancer drugs, survival, and ethics
The Association of Cancer Physicians responds to “Cancer drugs, survival, and ethics”
BMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i6487 (Published 05 December 2016) Cite this as: BMJ 2016;355:i6487
- Adam Dangoor, consultant medical oncologist1,
- Johnathan Joffe, consultant medical oncologist2,
- Adam Januszewski, medical oncology specialist trainee3,
- Janine Mansi, consultant medical oncologist4,
- David Cunningham, consultant medical oncologist5,
- Peter Selby, consultant medical oncologist6
- On behalf of 17 other authors and members of the Association of Cancer Physicians, UK
- 1Bristol Cancer Institute, Bristol Haematology and Oncology Centre, Bristol BS2 8ED, UK
- 2Huddersfield Royal Infirmary, Huddersfield, UK
- 3Imperial College, London, UK
- 4Guy’s and St Thomas’ Hospital, London, UK
- 5Royal Marsden Hospital, London, UK
- 6St James’s University Hospital, Leeds, UK
- adamd{at}doctors.org.uk
As UK health professionals specialising in the drug treatment of cancer, we think that Wise’s analysis strays into the territory of unbalanced opinion.1 We welcome discussion of topics that we debate ourselves; his article is a useful counterpoint to the hyperbole we often see in the media around incremental improvements in treatment. But he conflates problems from different …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.